Overview

Price chart · mood · technical indicators

GSK

GlaxoSmithKline PLC ADRstock Healthcare

Drug Manufacturers - General

$50.8935.69%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$35.45$61.70

Current: $50.89

Idea: EMA

1Y Return

+29.5%

Sharpe 3Y

0.63

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

GSK

+35.69%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio13.44Forward 20.00

EPS (TTM)$3.848.4% YoY

Profit margin17.8%HEALTHCARE

Market cap$103.01BLarge cap

Wall Street coverage

$57.65median target· current $43.45 (+32.7%)8 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 20.00
PEG ratio: 0.50
P/B: 4.27
P/S (TTM): 3.14
EV/EBITDA: 9.18

Profitability & growth

ROE (TTM): 40.9%
Operating margin: 36.3%
Revenue growth YoY: 1.5%
Dividend yield: 3.5%
Beta: 0.30

Last earnings

Apr 29, 2026 · Estimate $1.20 · Reported $1.26

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About GlaxoSmithKline PLC ADR

Company profile

GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NYSE
Country: USA
Currency: USD

Company profile

HQ: 79 NEW OXFORD STREET, LONDON, UNITED KINGDOM
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$103.01B

Shares outstanding$2.00B

52W high$61.21

52W low$34.48

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

GSK

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

GSK plc (LON:GSK) Given Consensus Recommendation of "Hold" by Analysts

GSK (GSK) Completes $950M Acquisition to Expand Drug Pipeline

How Gsk Plc American Depositary Shares (each Representing Two) (GSK) Affects Rotational Strategy Timing

GSK (NYSE: GSK) details April 2026 total voting rights and share capital

Dodge & Cox discloses 4.93% stake in GSK as of April 28, filing says

Q1 2026 GSK plc Earnings Call Transcript

JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited

Earnings call transcript: GSK Q1 2026 results miss expectations, stock drops

GSK plc 2026 Q1 - Results - Earnings Call Presentation (NYSE:GSK)

GSK posts Q1 beat and reaffirms outlook (GSK:NYSE)

GSK Profit Beats Estimates on HIV, Cancer Medicines

GSK delivers strong Q1 performance and start to 2026

Glaxo: Q1 Earnings Snapshot

GSK posts quarterly profit, sales beat in boost for new CEO Miels

[Press release] GSK: Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA

CFO Julie Brown’s 2023 GSK (NYSE: GSK) share award vests 82%

GSK CFO Julie Brown Receives Vested Performance Share Award

Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA

Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA

GSK says FDA sets 26 October 2026 PDUFA date for bepirovirsen

About GlaxoSmithKline PLC ADR

Classification

Company profile

GSK

Market Comparison

GSK Market Analysis

Overview

GSK

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

GSK plc (LON:GSK) Given Consensus Recommendation of "Hold" by Analysts

GSK (GSK) Completes $950M Acquisition to Expand Drug Pipeline

How Gsk Plc American Depositary Shares (each Representing Two) (GSK) Affects Rotational Strategy Timing

GSK (NYSE: GSK) details April 2026 total voting rights and share capital

Dodge & Cox discloses 4.93% stake in GSK as of April 28, filing says

Q1 2026 GSK plc Earnings Call Transcript

JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited

Earnings call transcript: GSK Q1 2026 results miss expectations, stock drops

GSK plc 2026 Q1 - Results - Earnings Call Presentation (NYSE:GSK)

GSK posts Q1 beat and reaffirms outlook (GSK:NYSE)

GSK Profit Beats Estimates on HIV, Cancer Medicines

GSK delivers strong Q1 performance and start to 2026

Glaxo: Q1 Earnings Snapshot

GSK posts quarterly profit, sales beat in boost for new CEO Miels

[Press release] GSK: Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA

CFO Julie Brown’s 2023 GSK (NYSE: GSK) share award vests 82%

GSK CFO Julie Brown Receives Vested Performance Share Award

Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA

Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA

GSK says FDA sets 26 October 2026 PDUFA date for bepirovirsen

About GlaxoSmithKline PLC ADR

Classification

Company profile

GSK

Market Comparison